Table 2.

Initial chemotherapeutic regimen.

Regimen	With rituximab (N = 18) (number, column percentage)	Without rituximab (N = 17) (number, column percent)	Total (N = 35) (number, column percent)
HyperCVAD	17 (94.4%)	9 (52.9%)	26 (74.2%)
CODOX-M/IVAC	1 (5.6%)	1 (5.9%)	2 (5.7%)
CALGB 9251	0	7 (41.2%)	7 (20.0%)

HyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of methotrexate and cytarabine; R-HyperCVAD, rituximab + HyperCVAD; CODOX-M-IVAC, cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, ara-C.